Results 11 to 20 of about 728 (161)

Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. [PDF]

Eur Heart J
Background and Aims The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations between clinical ...
Coats CJ, Masri A, Barriales-Villa R, Abraham TP, Brinkley DM, Claggett BL, Hagege A, Hegde SM, Ho CY, Kulac IJ, Lee MMY, Maron MS, Olivotto I, Owens AT, Solomon SD, Tfelt-Hansen J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Januzzi JL.   +23 more
europepmc   +14 more sources

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American College of Cardiology
BACKGROUND Aficamten, a next-in-class cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) and lowered resting and Valsalva left ventricular outflow (LVOT) gradients in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in ...
Sheila Hegde, Ahmad Masri, Roberto Barriales Villa   +2 more
exaly   +6 more sources

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. [PDF]

Nat Cardiovasc Res
Hypertrophic cardiomyopathy (HCM) is an inherited disease of the sarcomere resulting in excessive cardiac contractility. The first-in-class cardiac myosin inhibitor, mavacamten, improves symptoms in obstructive HCM. Here we present aficamten, a selective
Hartman JJ, Hwee DT, Robert-Paganin J, Chuang C, Chin ER, Edell S, Lee KH, Madhvani R, Paliwal P, Pernier J, Sarkar SS, Schaletzky J, Schauer K, Taheri KD, Wang J, Wehri E, Wu Y, Houdusse A, Morgan BP, Malik FI.   +19 more
europepmc   +6 more sources

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. [PDF]

J Am Coll Cardiol
BACKGROUND A primary goal in treating obstructive hypertrophic cardiomyopathy (oHCM) is to improve patients’ health status: their symptoms, function, and quality of life. The health status benefits of aficamten, a novel cardiac myosin inhibitor, have not
Sherrod CF, Saberi S, Nassif ME, Claggett BL, Coats CJ, Garcia-Pavia P, Januzzi JL, Lewis GD, Ma C, Maron MS, Miao ZM, Olivotto I, Veselka J, Butzner M, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Spertus JA.   +20 more
europepmc   +7 more sources

Clinical Evaluation of Drug–Drug Interactions With Aficamten [PDF]

Clinical and Translational Science
Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Neha Maharao, Donghong Xu, Punag Divanji, Tyrell J. Simkins, Jianlin Li, Camelia Dumitrescu, Priyanka Solanki, Adrienne Griffith, Stephen B. Heitner, Stuart Kupfer, Polina German, Justin D. Lutz   +11 more
doaj   +3 more sources

Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy. [PDF]

JACC: Heart Failure
BACKGROUND Disopyramide, used in obstructive hypertrophic cardiomyopathy (oHCM) for its negative inotropic properties mediated by its reduction in cytosolic calcium, has been recommended for decades as an option to relieve resistant obstruction ...
Ahmad Masri, M. Maron, T. Abraham, M. Nassif, R. Barriales-Villa, Ozlem Bilen, C. Coats, Perry Elliott, P. García-Pavía, Daniele Massera, I. Olivotto, A. Oręziak, A. Owens, S. Saberi, Scott D. Solomon, A. Tower-Rader, S. Heitner, D. Jacoby, C. Melloni, Jenny Wei, M. Sherrid   +20 more
semanticscholar   +9 more sources

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

New England Journal of Medicine
BACKGROUND One of the major determinants of exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract obstruction ...
Fady I Malik, Stuart Kupfer, Stephen B Heitner   +2 more
exaly   +7 more sources

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. [PDF]

Journal of the American College of Cardiology
BACKGROUND Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has not been fully defined.
M. Maron, A. Masri, M. Nassif, R. Barriales-Villa, T. Abraham, M. Arad, Nuno Cardim, L. Choudhury, B. Claggett, C. Coats, H. Düngen, P. García-Pavía, A. Hagège, J. Januzzi, I. Kulac, M. Lee, G. Lewis, Changsheng Ma, Michelle Michels, A. Oręziak, A. Owens, John A. Spertus, Scott D. Solomon, J. Tfelt-Hansen, Marion van Sinttruije, Josef Veselka, Hugh Watkins, D. Jacoby, S. Heitner, S. Kupfer, F. Malik, L. Meng, A. Wohltman, I. Olivotto   +33 more
semanticscholar   +9 more sources

Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy. [PDF]

Journal of the American College of Cardiology
BACKGROUND Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and left atrial dilation, which can be associated with progressive heart failure, atrial fibrillation, and ...
A. Masri, R. Cardoso, T. Abraham, B. Claggett, C. Coats, S. M. Hegde, I. Kulac, M. Lee, M. Maron, B. Merkely, Michelle Michels, I. Olivotto, A. Oręziak, D. Jacoby, S. Heitner, S. Kupfer, F. Malik, L. Meng, Scott D. Solomon, A. Wohltman, Raymond Y. Kwong, Christopher M. Kramer   +21 more
semanticscholar   +8 more sources

Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4 [PDF]

Journal of Cardiac Failure
BACKGROUND This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). METHODS Patients with symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤30
Ahmad Masri, Mark V Sherrid, Roberto Barriales Villa   +2 more
exaly   +7 more sources